You're signed outSign in or to get full access.
Catalys Pacific, LLC
Catalys Pacific is an independent venture capital firm headquartered in Tokyo, Japan, with additional offices in San Francisco, California and Kanagawa, Japan. The firm focuses on early-stage investments in the life sciences sector, particularly biotherapeutics, MedTech, diagnostics, and biotechnology. Catalys Pacific aims to bridge innovation ecosystems in Japan and the United States, supporting the development of global healthcare solutions and fostering transpacific partnerships. The firm employs a team of dedicated R&D experts and advisors to identify, create, and invest in asset-centric bioventure companies to address significant unmet medical needs worldwide. Founded to serve visionary entrepreneurs and companies in life sciences, its team consists of less than 25 professionals with broad experience in academia, biotechnology, venture capital, and the pharmaceutical industry.
Investment Strategy
Catalys Pacific executes a transpacific investment strategy, identifying and nurturing early-stage biotherapeutics, MedTech, and diagnostics companies, with an emphasis on cross-border opportunities between Japan and the United States. The firm creates, invests in, and supports asset-centric global bioventure companies, leveraging partnerships within academic, venture, and pharmaceutical circles to advance science and improve patient outcomes. Catalys Pacific's approach features hands-on management, deep due diligence, and a network-driven strategy to foster transformative life science solutions and global market entry, particularly facilitating innovation flow between the U.S. and Japan.
Latest 13F Filing Activity
Catalys Pacific, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 2 equity positions with a total 13F market value of $132M. The fund increased holdings in Phathom Pharmaceuticals, Inc., Mineralys Therapeutics, Inc.. Catalys Pacific, LLC reduced exposure to Mineralys Therapeutics, Inc., Phathom Pharmaceuticals, Inc..
Top Holdings
Equity Positions (2)
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more